Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results
Arcturus Therapeutics(US:ARCT) Invezz·2025-10-22 20:53Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) tumbled by more than 56% on Wednesday after the company reported interim results from its Phase 2 study of ARCT-032, an inhaled mRNA therap... ...